The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing ...

Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim is the latest global top 20 biopharma company to commit ...

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...

U.S. Animal Health Country Managing Director at Boehringer Ingelheim. "Each year, we invest nearly 12 percent of our sales into researching and developing products that will advance the health of ...

"Boehringer Ingelheim has a forward-looking approach to unifying its technology and data landscape to rapidly deliver therapies that improve human and animal health," said Tom Schwenger, president and ...